(ChemotherapyAdvisor) – The halichondrin B analog eribulin mesylate was found to be well tolerated and demonstrated activity in patients with non–small-cell lung cancer sensitive to taxane, according to results of a open-label Phase 2 study published in the March 2012 issue of the Journal of Thoracic Oncology.
The study included 66 patients previously treated with up to two prior platinum- and taxane-based regimens for metastatic disease or as adjuvant therapy. Patients were stratified by taxane-sensitivity: those taxane-sensitive had progression >90 days after taxane, while those taxane-resistant had progression ≤90 days after taxane. Eribulin 1.4mg/m2 was administered as an IV infusions days 1 and 8 every 21 days. Primary end point was objective response rate; secondary end points included progression-free survival (PFS) and overall survival (OS).
Overall objective response rate was 5%, and median duration of response was 7.8 months. In patients who were taxane-sensitive, 3 of 45 patients (7%) achieved a partial response and 11 (24%) achieved stable disease for at least three months. In the taxane-resistant arm, no patients achieved a partial response and 4 of 21 (19%) achieved stable disease for at least three months.
Median PFS was 2.9 months in the taxane-sensitive arm and 1.2 months in the taxane-resistant arm; median OS was 12.6 and 8.9 months, respectively. Toxicities were primarily hematologic and two patients developed grade 3 neuropathy.
Eribulin mesylate is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.